COVID-19 resources / Clinical Research Insights and News

The Cohortias Blog

Stay informed

COVID-19 resources

Cohortias is bringing clinical research to Latin America, now proud to participate in COVID-19 clinical trials.

Our archive includes insights from our experts as they discuss lessons learned over the past three months in managing COVID-19’s impact on trials in Latin America and around the world.

Our blog posts provide insights into what companies should be doing now to prepare for the upcoming ‘new normal’.

covid-19-vaccine-Latam

Brazil authorizes Butanvac vaccine shot for volunteers in clinical trial.

Brazilian health regulator Anvisa on Wednesday gave the go-ahead for the Butanvac COVID-19 vaccine developed by Sao Paulo’s Butantan Institute biomedical center to be used on volunteers in clinical trials.

clinical-trials-latin-america

Clinical trials Latin America – Clinical trial of HIV vaccine.

The University of Oxford today started vaccinations of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK.

covid-19-vaccine-Latam

COVID-19 – Final phase of COVID new vaccine.

The Phase 2 trials already showed a strong immune response after a single shot in participants who had previously contracted the coronavirus.

clinical-trials-latin-america

CRO in Latin America – The Potential Of LATAM.

The presence of clinical research in Latin America growing steadily in the last decade, mainly because of cost effectiveness and excellent patient recruitment.

COVID-19 Research - Free Consultation

The clinical development journey is fraught with pitfalls and roadblocks; COVID-19 has almost overnight added to the complexity. Innovations, technologies and reinvented processes can help. Our experienced team of experts shares experiences, lessons learned and tips to help you mitigate risk in the current environment while implementing some of the industry’s latest innovations.

covid clinical trials

The presence of clinical research in Latin America has been growing steadily for the last decade, mainly because of cost effectiveness, excellent patient recruitment and the emergence of FDA approved regulatory agencies.